Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy

Journal of the Neurological Sciences

Volumn 264, Issue 1-2, 2008, Pages 145-150

  Eggert, Martin ^a   Goertsches, Robert ^b   Seeck, Ulrike ^a   Dilk, Silvia ^b   Neeck, Gunther ^a   Zettl, Uwe K ^b  

^a Center of Rheumatology   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Blood lymphocytes; Glucocorticoid pulse therapy; Multiple sclerosis; NF B

Indexed keywords

DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; PROTEIN P50; SYNAPTOTAGMIN I;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DNA BINDING; DRUG PULSE THERAPY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; BIOLOGICAL MARKERS; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NF-KAPPA B; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR RELA; TREATMENT OUTCOME;

EID: 36549059089     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.08.026     Document Type: Article

References (37)

1. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 23 (2005) 683-747
2. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 46 (1996) 907-911
3. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
4. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG), Rieckmann P. Escalating immunomodulatory therapy of multiple sclerosis. Nervenarzt 70 (1999) 371-386
5. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG), Rieckmann P. Escalating immunomodulatory therapy of multiple sclerosis: update (September 2006). Nervenarzt 77 (2006) 1506-1518
6. Rieckmann P., Toyka K.V., Bassetti C., Beer K., Beer S., and Buettner U. Multiple sclerosis therapy consensus group. Escalating immunotherapy of multiple sclerosis-new aspects and practical application. J Neurol 251 (2004) 1329-1339
7. Stangel M., Gold R., Gass A., Haas J., Jung S., Elias W., et al. Current issues in immunomodulatory treatment of multiple sclerosis-a practical approach. J Neurol 253 (2006) I32-I36
8. Schmidt J., Gold R., Schonrock L., Zettl U.K., Hartung H.P., and Toyka K.V. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 123 (2000) 1431-1441
9. Leussink V.I., Jung S., Merschdorf U., Toyka K.V., and Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 58 (2001) 91-97
10. Beck R.W., Cleary P.A., Anderson M.M., Keltner J.L., Shults W.T., Kaufman D.I., et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326 (1992) 581-588
11. Cazzato G., Mesiano T., Antonello R., Monti F., Carraro N., Torre P., et al. Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur Neurol 35 (1995) 193-198
12. Goodkin D.E., Kinkel R.P., Weinstock-Guttman B., VanderBrug-Medendorp S., Secic M., Gogol D., et al. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 51 (1998) 239-245
13. Andersson P.B., and Goodkin D.E. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J Neurol Sci 18 (1998) 16-25
14. Reichardt H.M., Tuckermann J.P., Bauer A., and Schütz G. Molecular genetic dissection of glucocorticoid receptor function in vivo. Z Rheumatol 2 (2000) 1-5
15. Eggert M., Schulz M., and Neeck G. Molecular mechanisms of glucocorticoid action in rheumatic autoimmune diseases. J Steroid Biochem Mol Biol 77 (2001) 185-191
16. Herrlich P. Cross-talk between glucocorticoid receptor and AP-1. Oncogene 20 (2001) 2465-2475
17. Eggert M., Kluter A., Zettl U.K., and Neeck G. Transcription factors in autoimmune diseases. Curr Pharm Des 10 (2004) 2787-2796
18. Gold R., Buttgereit F., and Toyka K.V. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 117 (2001) 1-8
19. Zipp F., Wendling U., Beyer M., Grieger U., Waiczies S., Wagenknecht B., et al. Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells. J Neuroimmunol 110 (2000) 214-222
20. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109 (2002) S81-S96
21. Baeuerle P.A., and Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12 (1994) 141-179
22. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6853-6866
23. Palanki M.S. Inhibitors of AP-1 and NF-kappa B mediated transcriptional activation: therapeutic potential in autoimmune diseases and structural diversity. Curr Med Chem 9 (2002) 219-227
24. Chen F.E., and Ghosh G. Regulation of DNA-binding by Rel/NF-kappa B transcription factors: structural views. Oncogene 18 (1999) 6845-6852
25. Bacher S., and Schmitz M.L. The NF-kappaB pathway as a potential target for autoimmune disease therapy. Curr Pharm Des 10 (2004) 2827-2837
26. Flores N., Duran C., Blasco M.R., Puerta C., Dorado B., Garcia-Merino A., et al. NF kappaB and AP-1 DNA binding activity in patients with multiple sclerosis. J Neuroimmunol 135 (2003) 141-147
27. Eggert M., Klüter A., Rusch D., Schmidt K.L., Dotzlaw H., Schulz M., et al. Expression analysis of the glucocorticoid receptor and the nuclear factor-kB subunit p50 in lymphocytes from patients with rheumatoid arthritis. J Rheumatol 29 (2002) 2500-2506
28. Beato M. Gene regulation by steroid hormones. Cell 56 (1989) 335-344
29. Muller M., and Renkawitz R. The glucocorticoid receptor. Biochim Biophys Acta 1088 (1991) 171-182
30. McKay L.I., and Cidlowski J.A. Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism. Mol Endocrinol 12 (1998) 45-56
31. Ray A., and Prefontaine K.E. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci 91 (1994) 752-756
32. Caldenhoven E., Liden J., Wissink S., Van de Stolpe A., Raaijmakers J., Koenderman L., et al. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for antiinflammatory action of glucocorticoids. Mol Endocrinol 9 (1995) 401-412
33. Auphan N., DiDonato J.A., Rosette C., Helmberg A., and Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270 (1995) 232-233
34. Scheinman R.I., Cogswell P.C., Lofquist A.K., and Baldwin Jr. A.S. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270 (1995) 283-286
35. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122 (2005) 707-721
36. Weinshenker B.G., Bass B., Rice G.P., Noseworthy J., Carriere W., Baskerville J., et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112 (1989) 133-146
37. Van Winsen LM., Muris D.F., Polman C.H., Dijkstra C.D., van den Berg T.K., and Uitdehaag B.M. Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis. J Clin Endocrinol Metab 90 (2005) 734-740